Autoimmune diseases

Pain, fatigue and fluctuating symptoms can affect everyday life, while disease activity and organ involvement differ between people. Rheumatoid arthritis and lupus require their own diagnostic and treatment discussions.

The treating rheumatology team should remain central to disease management. Any additional proposal must be considered alongside current medicines, monitoring, disease activity and the risks of changing established care.

Research questions must be specific to the disease, cell product and intended use. Describing immune modulation is not evidence of a generic immune reset. No replacement for established disease management is implied.

Look for human clinical evidence for the exact product and use. Study design, comparison groups, follow-up, meaningful outcomes and harms all affect how a finding should be interpreted. A laboratory mechanism or individual testimonial is not sufficient proof.

1. What is my precise diagnosis, and which established options should I consider?
2. What cell product and intended use are being proposed?
3. What evidence applies to people in my circumstances, and what remains uncertain?
4. What are the risks, alternatives and consequences of delaying existing care?
5. What permissions, responsible clinicians and follow-up arrangements would apply?

Take time to consider the answers and seek an independent opinion. No decision or travel booking should be based on this website alone.

Independent source: ISSCR patient information

These resources provide background, not NovaCell endorsement or local authorization.

All condition guides